Chiropractors in Laurel, MD Accepting Medicare

24 Chiropractors found. Showing 21 - 24

Allcare Injury Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 525 Main St Ste 105, Laurel, MD 20707 Phone: 800-988-1744    Fax: 202-986-2002

Mcauliffe Chiropractic Office Chiropractor Medicare: Medicare Enrolled Practice Location: 8375 Cherry Ln, Laurel, MD 20707 Phone: 301-776-0756

Laurel Regional Chiropractic, Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 13992 Baltimore Ave Ste 201a, Laurel, MD 20707 Phone: 301-953-0256

Tracy Nana Asare, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 14201 Laurel Park Dr Ste 212, Laurel, MD 20707 Phone: 240-341-0005    Fax: 240-341-0004

News Archive

Educational events for physicians who diagnose and treat prostate cancer

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a series of educational events designed for radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians who diagnose and treat patients with prostate cancer.

Influenza pandemic planning needed to ensure that pregnant women and newborns receive priority treatment

Pregnant women and newborns are at greatest risk in a flu epidemic, but more planning must be done to ensure that they receive priority treatment should an outbreak occur, according to a University of Pittsburgh Medical Center (UPMC) and University of Pittsburgh study.

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

Read more Medical News

› Verified 8 days ago

• 1
• 2(current)